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gers, toes, heels, nose, ears and sometimes 
knees and elbows  [1, 2] . Chilblain lupus typ-
ically manifests itself during cold and damp 
times of the year or after a critical drop in 
temperature and is often difficult to distin-
guish clinically and histologically from 
true cold-induced chilblains  [1, 3] . The 
presence of antinuclear antibodies and in 
few cases anti-Ro/SSA antibodies or rheu-
matoid factor as well as a positive lesional 
direct immunofluorescence are helpful to 
establish the diagnosis of chilblain lupus  [4, 
5] and to distinguish this form of lupus ery-
thematosus from lupus pernio (cutaneous 
sarcoidosis) and acral vasculitis/vasculopa-
thy due to cryoglobulinaemia.
 Chilblain lupus usually occurs sporad-
ically in middle-aged women and is rarely 
observed in children. We recently de-
scribed a German family exhibiting an au-
tosomal dominant form of chilblain lupus, 
which manifests itself in early childhood 
 [6] . We mapped its genetic locus to chro-
mosome 3p and subsequently identified a 
heterozygous mutation in the gene encod-
ing the 3  -5  DNA exonuclease TREX1 af-
fecting a highly conserved residue within 
the catalytic centre as the cause of familial 
chilblain lupus in this family  [6, 7] . Until 
to date, only 1 additional case of familial 
chilblain lupus caused by a mutation in the 
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 Abstract 
 Chilblain lupus erythematosus is a rare form 
of cutaneous lupus erythematosus charac-
terized by bluish red infiltrates in acral loca-
tions of the body mostly affecting middle-
aged women. We recently described a 
familial form of chilblain lupus manifesting 
in early childhood caused by a heterozygous 
mutation in the  TREX1 gene, which encodes 
a 3  -5  DNA exonuclease. Thus, familial chil-
blain lupus represents the first monogenic 
form of cutaneous lupus erythematosus. 
Here we describe the unusual clinical course 
of this newly defined genodermatosis in an 
18-year-old female member of the family in 
which familial chilblain lupus was originally 
described.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Chilblain lupus is a rare form of chronic 
cutaneous lupus erythematosus character-
ized by tender, bluish red swellings and 
nodules on acral surfaces such as the fin-
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 TREX1 gene has been described in a pedi-
gree of Bangladeshi origin  [8] . During cas-
pase-independent apoptosis initiated by 
granzyme A, TREX1 translocates into the 
nucleus and causes single-stranded DNA 
(ssDNA) damage by removing nucleotides 
from nicked 3 -´ends, thus reducing the 
possibility of repair by rejoining the nicked 
ends  [9] .
 Mutations in  TREX1 have been associ-
ated with a range of disorders with varying 
degrees of phenotypic overlap. These in-
clude Aicardi-Goutières syndrome, a rare 
infantile encephalopathy mimicking con-
genital viral infection characterized by 
basal ganglion calcification and chilblain-
like lesions  [10, 11] , autosomal dominant 
retinal vasculopathy with cerebral leuko-
dystrophy  [12] as well as systemic lupus 
erythematosus (SLE)  [13] . While the mo-
lecular mechanisms underlying the di-
verse phenotypic spectrum of  TREX1 mu-
tations are not fully understood, function-
al analysis suggests a loss-of-function 
mechanism consistent with haplo-insuffi-
ciency  [7, 10] . In this report we provide a 
detailed description of the clinical course 
of a severely affected member from the 
German pedigree with familial chilblain 
lupus, in which this novel genodermatosis 
was originally described  [6] .
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 Case Report 
 The patient presented at 2 years of age 
with painful bluish red infiltrates on her 
fingers which were precipitated by sud-
den temperature changes during the cold 
season. The cutaneous lesions resembled 
those seen in her mother and brother, 
who both experienced similar recurrent 
skin changes confined to fingers and toes 
since early childhood. At the age of 9 
years, she was admitted to the hospital for 
the first time because of worsened skin le-
sions after swimming lessons at school. 
At this time her fingers and the rims of 
her soles were affected by tender plaque-
like lividoid infiltrates. Apart from skin 
findings, her physical examination was 
unremarkable. Laboratory investigations 
revealed the presence of antinuclear anti-
bodies with a titre of 1: 160 and a homoge-
neous pattern, reduced levels of comple-
ment C4 (0.18 g/l, normal range 0.2–0.49) 
and the presence of C3d-binding immune 
complexes. Anticardiolipin IgG and IgM 
as well as serum IgA and IgG were slight-
ly elevated. There was no serological evi-
dence for viral or bacterial infections. 
Tests for cryoglobulins and cryofibrino-
gen were negative, and all other labora-
tory values including complete blood cell 
count with differential, coagulation and 
liver function tests as well as urine analy-
sis were within normal ranges. Nailfold 
capillary microscopy showed no patho-
logical findings. Although a skin biopsy 
was not performed at that time, the diag-
nosis of cutaneous lupus erythematosus 
was suspected. Under stringent cold pro-
tection and skin care with urea-contain-
ing ointments, the patient experienced 
improvement of skin symptoms during 
the following years until the age of 16, 
when she was hospitalized for anorexia 
and again suffered from a severe attack of 
erythematous skin lesions on fingers and 
toes.
 At 18 years of age, she was referred to 
the hospital during late spring with bluish 
red infiltrates on erythematous skin par-
tially covered with fine scales on the dorsal 
sides of fingers and toes ( fig. 1 ). The fin-
gernails were thickened with areas of yel-
low brownish discolouration and periph-
eral onycholysis. In addition, multiple ten-
der subcutaneous erythematous infiltrates 
without epidermal alteration were seen on 
the thighs, buttocks, knees as well as on 
the left cheek ( fig. 1 ). The lesions on the 
thighs were up to 4 cm in diameter and 
presented as deep, palpable infiltrations 
with a dark red to purple colour. Her com-
plaints had increased during the last 4 
a
b
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 Fig. 1. Dermatological findings. Papular bluish red infiltrates on erythematous skin with 
fine white scaling extend on the dorsal sides of the fingers ( a ) and toes ( b ). Cutaneous 
lesions on the left cheek ( c ) and the thighs ( d ) appear as extended tender purple red sub-
cutaneous infiltrates. 
 Fig. 2. Histology of lesional skin.  a Biopsy from the finger showing vacuolar degenera-
tion of basal keratinocytes, perivascular lymphocytic infiltration with partial alteration 
of the epidermal junction zone. Haematoxylin-eosin stain. Original magnification 
 ! 100.  b Biopsy from the thigh showing perivascular oedema and perivascular lympho-
cytic infiltration without epidermal involvement. Haematoxylin-eosin stain. Original 
magnification  ! 50.  c Alcian blue staining of the biopsy from the thigh reveals marked 
mucin deposition throughout the entire dermis extending to the subcutis. Original mag-
nification  ! 50. 
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months during which she was under men-
tal stress due to her final examinations at 
school. She did not complain of painful 
joints or tendons, palpitations, mental 
changes, hair loss, light sensitivity, oral ul-
cerations or gastro-intestinal problems 
typically seen in SLE.
 Her body mass index was 17.9 (normal 
range: 18.4–25.2), and her blood pressure 
was 90 over 40 mm Hg. Apart from brady-
cardia with a heart rate of 44/min, ECG, 
echocardiography and abdominal ultra-
sound were without any pathological find-
ings.
 Histological examination of lesional 
skin from the finger showed a partially 
atrophic epidermis with vacuolar degen-
eration of basal keratinocytes ( fig. 2 a). 
Throughout the dermis, the vessel walls 
appeared swollen, and perivascular lym-
phocytic infiltrations with hydropic de-
generation of the epidermal junction zone 
were seen. Alcian blue staining revealed 
marked deposition of mucin within the 
dermis. Epidermal findings in lesional 
skin from the thigh were rather discrete 
and included focal parakeratosis as well as 
follicular hyperkeratosis, while dermal 
changes were much more pronounced. 
Throughout the dermis extending to the 
upper subcutis, swollen vessel walls were 
surrounded by perivascular and periad-
nexal oedema as well as marked lympho-
cytic infiltrations ( fig. 2 b). Prominent de-
posits of mucin were present throughout 
the entire dermis and parts of the subcutis 
( fig. 2 c). Direct immunofluorescence re-
vealed band-like IgM and C3 depositions 
along the basement membrane zone on le-
sional skin from the finger and dorsal 
thigh ( fig. 3 a, b). Together, the histological 
findings were consistent with cutaneous 
lupus erythematosus of the fingers and 
plaque-like mucinosis of the thigh.
 Laboratory examinations showed re-
duction of erythrocyte count of 3.77 cells/
l (normal range: 4.2–5.4) and a haemat-
ocrit of 0.34 (normal range: 0.37–0.47). 
Haemoglobin was within the normal 
range. Serum levels of IgA and IgG were 
slightly elevated. The concentration of 
complement C3 (0.91 g/l; normal: 0.9–1.8) 
and C4 (0.17 g/l; normal: 0.1–0.4) were 
within the lower range of normal. Com-
plement C3c-, C3d- and C1q-binding im-
mune complexes, anticardiolipin and an-
tiphospholipid IgG and IgM antibodies 
were negative. A complete blood cell count 
with differential, kidney and liver func-
tion tests, protein electrophoresis as well 
as coagulation tests (Quick, partial throm-
boplastin time, international normalized 
ratio) were unremarkable. Cryoglobulins 
or cryofibrinogen were absent. A 24-hour 
urine status did not show increased pro-
tein or albumin levels. The patient HLA 
alleles were as follows: HLA-A1/A2, HLA-
B8/B44 (12), HLA-Bw6/Bw4, HLA-Cw7/
Cw7, HLA-DRB1 0301–0311 (DR3)/0401–
0425 (DR4), HLA-DQB1 0201/0301.
 Indirect immunofluorescence of Hep-
2 cells using the patient’s serum showed a 
markedly elevated antinuclear antibody
titre of 1: 1,000 with homogeneous stain-
ing of nucleoplasma and chromosomes 
( fig. 3 c, d). Auto-antibodies against Ro,
La, nucleosomes, histones and double-
stranded DNA were undetectable. How-
ever, auto-antibodies against ssDNA were 
weakly positive with 27 IU/ml ( ! 25 nega-
tive; 25–35 weakly positive,  1 35 IU/ml 
positive). Interferon - levels in serum 
were not increased. Nailfold capillary mi-
croscopy showed reduced capillary densi-
ty with shape deformities such as elonga-
tion, partial grouping and dilatation on all 
fingers.
 Based on the clinical, serological and 
histological findings, the diagnosis of chil-
blain lupus following the criteria of Su et 
al.  [2]  was confirmed. At this time several 
members of her family including her 
brother and mother had been diagnosed as 
having autosomal dominant familial chil-
blain lupus caused by a heterozygous mu-
tation in the  TREX1 gene. This mutation 
could also be confirmed in the case of the 
patient. Immunofluorescence staining of 
TREX1 of lesional skin revealed high ex-
pression of  TREX1 in keratinocytes, endo-
thelial and mononuclear cells. In compar-
ison to normal skin, a slightly higher ex-
pression of  TREX1 within the cytoplasm 
of keratinocytes was noted ( fig. 4 ).
 The patient had been on a low dose of 
100 mg acetylsalicylic acid (ASA) daily for 
the past 3 months prior to admission with-
out clinical improvement. Due to her low 
blood pressure, therapy with the vasodila-
tory calcium channel blocker nifedipine 
was not considered initially. Instead, ther-
apy with topical steroids and hydroxychlo-
roquine at a low dose of 200 mg daily was 
started. In addition, the patient was in-
a b
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 Fig. 3. Immunofluorescence. Direct immunofluorescence staining of lesional skin from 
the thigh ( a ) and finger ( b ) reveals band-like deposits of C3 in the dermal-epidermal 
junction zone. Indirect immunofluorescence using the patient’s serum shows a homo-
geneous staining of the nucleoplasma of Hep-2 cells ( c ) as well as staining of chromatin 
of mitotic cells ( d ) along with a peculiar weak staining of the centre of chromatin. 
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structed to prevent exposure to cold. Ther-
apy was well tolerated, and after 4 months 
of treatment the clinical manifestations on 
her hands, feet and thighs had markedly 
improved. During the cold winter season, 
amlodipine 5 mg daily was added to her 
medication. The drug was well tolerated 
and improved peripheral circulation. The 
cold-induced lesions appeared less livi-
doid, and heatable finger gloves prevented 
cold-induced ulcerations.
 Discussion 
 The clinical presentation of this patient 
with chilblain lupus erythematosus is re-
markable because of the extensive skin 
findings and the progressive course dur-
ing adolescence, although the diagnostic 
criteria for SLE were formally never ful-
filled. This is in contrast to the clinical 
presentation of other affected members of 
her family, in whom chilblain lesions tend 
to improve with age and progression to 
SLE has not been reported even in old age 
 [6] . In addition to typical chilblain lesions 
in acral locations, the patient also present-
ed with erythematous subcutaneous mu-
cin-rich infiltrates without epidermal in-
volvement on the thighs and the buttocks. 
This is reminiscent of LE tumidus lesions 
which are, however, usually smaller in size 
and located in sun-exposed areas  [1] . 
Strong mucin deposition in nodular or 
papular form is rarely seen in discoid lupus 
erythematosus and occurs more frequent-
ly in patients with SLE accounting for 
about 2% of these cases  [14, 15] . In addi-
tion, Jessner’s lymphocytic infiltration of 
the skin has been recognized as a cutane-
ous form of lupus erythematosus that does 
not show epidermal involvement  [16, 17] .
 The early onset of the disease can be 
explained by the genetic defect in the 
 TREX1 gene identified in this family, al-
though the exact molecular mechanisms 
that lead to chilblain lupus remain not ful-
ly understood. This mutation [c.52G ] A, 
leading to the substitution of an aspartate 
with an asparagine at position 18 of the 
TREX1 peptide (D18N)] affects a highly 
conserved residue within the catalytic 
centre of the TREX1 enzyme and has been 
shown to impair DNA damage during 
granzyme-A-mediated apoptosis  [6, 7] . 
Thus, this defect may be responsible for 
improper clearance of altered DNA caus-
ing intracellular accumulation of ssDNA, 
which in turn induces – through yet un-
identified intracellular sensors and signal-
ling pathways – an immune-mediated in-
flammatory response  [7] . This is consis-
tent with our finding of a strong expression 
of TREX1 in keratinocytes and vascular 
cells of the skin, the site of inflammation. 
Moreover, recent evidence suggests that 
intracellular accumulation of ssDNA in 
TREX1-deficient cells may be due to de-
fects in the degradation of nucleic acids de-
rived from chronic cell cycle checkpoint 
activation or from endogenous retrovirus-
es  [18, 19] . This notion is supported by the 
finding of auto-antibodies against ssDNA 
in the patient’s serum, albeit at low levels, 
which suggest an auto-immune response 
to ssDNA. In view of the fact that hetero-
zygous carriers of  TREX1 variants have a 
high risk for developing SLE  [13] , these 
findings underpin the importance of de-
fects in intracellular nucleic acid metabo-
lism for the pathogenesis of lupus erythe-
matosus.
 It is possible that additional permissive 
factors contributed to the clinical course 
in this patient. Thus, a low body mass in-
dex as well as pathological capillary chang-
es observed in this patient may have played 
a role during exacerbation of chilblain lu-
pus  [20] . In fact, precipitation of chilblain 
lupus by anorexia in an adolescent male 
has recently been reported  [21] . Because of 
the strong linkage disequilibrium of the 
HLA allele HLADRB10301 (HLA-DR3) 
and the C4 null allele, it is also possible 
that the low C4 levels in this patient are 
genetically determined  [22] . C4 plays a 
critical role in the processing of immune 
complexes, and deficiency of C4 is known 
to confer susceptibility to SLE  [23, 24] .
 The therapy of chilblain lupus primar-
ily includes protection from cold  [25] and 
improvement of the peripheral blood flow 
with ASA or nifedipine  [20, 26] . Topical 
steroids may be of benefit in some patients 
 [27] . Hydroxychloroquine has been used 
with inconsistent success  [3] and usually 
requires continued treatment throughout 
the warm season  [2, 27] . The therapeutic 
effect of other immunosuppressive drugs 
such as cyclophosphamide or mycopheno-
late mofetil has been reported in single 
cases only  [21] . In the present case blood-
flow-enhancing intervention with ASA 
was not helpful, while treatment with hy-
droxychloroquine was highly effective.
a b c
 Fig. 4. Expression of  TREX1 . Lesional skin from the finger ( a ), 
thigh ( b ) and normal skin ( c ) was stained using mouse IgG1 anti-
mouse TREX1 antibody (BD Transduction Laboratories) as pri-
mary and goat F(ab’)2 anti-mouse IgG-AF546 antibody (Molecu-
lar Probes) as secondary antibody, respectively.  TREX1 is strong-
ly expressed within the cytoplasm of keratinocytes, vascular and 
mononuclear cells. In comparison to normal skin,  TREX1 is more 
highly expressed in affected skin. Negative control sections with-
out primary antibody were unstained (data not shown). Magnifi-
cation  ! 400. 
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 Taken together, the present case pro-
vides a detailed description of the unusual 
clinical course of a patient with familial 
chilblain lupus due to a mutation in  TREX1 
by demonstrating a rather progressive 
course with extended dermatological find-
ings. In addition, this case indicates that 
hydroxychloroquine may be an efficient 
therapeutic option for severe cases of fa-
milial chilblain lupus.
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